To discuss the molecular mechanism of Yiqi Jiedu Tongluo Granules，which was used for treating patients with post-hepatitis B liver cirrhosis，and to provide the theory foundation for it.Methods:Cases were randomly selected from the visitors in Dongzhimen Hospital from June 2015 to October 2017 with 15 healthy persons of Medical Examination Center，and 42 patients with post-hepatitis B liver cirrhosis of Hepatitis clinic.The patients with post-hepatitis B liver cirrhosis had been treated by entecavir.The patients were treated with Yiqi Jiedu Tongluo Granules for 6 months; The serum of the healthy persons，the patients before treatment，and the patients after treatment was collected.The method of ELISA was used to detect the serum level of VEGF and PDGF-AB.Results:The serum level of VEGF in patients with post-hepatitis B liver cirrhosis was increased than those of healthy persons，and after-treating was decreased than before-treating.But the level of VEGF was not statistically significant among groups (P>0.05).The serum level of PDGF-AB in patients with post-hepatitis B liver cirrhosis was significantly decreased than those of healthy persons (P<0.001); after-treating was increased than before-treating (P<0.05)，but was lower than those of healthy persons (P<0.05).Conclusion:The serum level of VEGF and PDGF-AB has some relativity with post-hepatitis B liver cirrhosis.Yiqi Jiedu Tongluo Granules can affect the serum level of VEGF and PDGF-AB，which may be one of its treatment mechanisms.